Perspective

**Is it time now to stop searching for other tumor markers for HCC apart from alpha-fetoprotein?**

**Ahmed Elsayed Mohamed** **Esmaiel**

A resident of Hepatology and Gastroenterology, Kafr Elsheikh Liver Research Center.

**Received:** 05 October 2021; **Accepted:** 12 October 2021; **Published:** 12 October 2021.

**\*Correspondence: Ahmed Elsayed Mohamed Esmaiel.**

**Email:** **ahmedesmaiel157@gmail.com**

**DOI:** [**https://doi.org/10.52378/fkha1952**](https://doi.org/10.52378/fkha1952)

**Cell phone:** +201019117613.

Abstract.

Despite the uncountable amount of tumor markers, no one shows superiority over alpha-fetoprotein. Also, liquid biopsies are used to diagnose HCC but are still under extensive research.

**Keywords:** hepatocellular carcinoma, alpha-fetoprotein, tumor markers.

Hepatocellular carcinoma (HCC) represents 85–90% of all liver malignancy; it is the fourth leading cause of cancer-related deaths, estimated to be responsible for nearly 9.1% of total death in 2012 **(1).**

AFP is not specific as a commonly used marker for diagnosing hepatocellular carcinoma (HCC). It can be elevated in chronic hepatitis B or C in the absence of cancer. It can also be increased in patients with cholangiocarcinoma and non-liver cancer such as gastric cancer **(2).**

Diagnosis of HCC can be made by radiology and laboratory investigations. Radiological diagnosis mainly depends on ultrasonography, triphasic computerized tomography (triphasic CT-scan), and dynamic magnetic resonance imaging (dynamic MRI). Ultrasonography (US) is most frequently the first imaging modality used in the evaluation of parenchymal organs of the abdomen due to its relatively low cost, wide availability, and non-invasiveness **(3).**

Also, AFP has low sensitivity, as it may be expected in up to 40% of HCC cases, especially early stages. So, AFP is a marker with poor sensitivity and specificity for diagnosing patients with HCC **(4).** Although it is the most widely used tumor marker for HCC as it is cheap, blood marker has sensitivity and specificity more than other tumor markers.

It’s a dilemma; does AFP still a standard marker in the diagnosis and prognosis of HCC, or do we need another marker?

Until now, no other tumor marker showed promising results compared to alpha-fetoprotein.

The American Association for the Study of Liver Diseases (AASLD) guidelines recommended that serum levels of alpha-fetoprotein (AFT) 200 ng/ml may be used instead of fine-needle cytology for diagnosis, especially in patients with liver cirrhosis **(5).**

Nowadays, many tumor markers are used in conjunction with radiology for diagnosing HCC without extra benefit except in limited cases (atypical HCC with a standard or low level of alpha-fetoprotein or cases that did not give the classic picture of HCC during triphasic CT).

**Footnotes.**

**Citation of this article:** Esmaiel A. Is it time now to stop searching for other tumor markers for HCC apart from alpha-fetoprotein? African journal of gastroenterology and hepatology [Internet]. Egypt’s Presidential Specialized Council for Education and Scientific Research; 2021 Oct 12;4(1):26-28. Available from: <http://dx.doi.org/10.52378/fkha1952>.

**Peer- Reviewers:** Mohamed Hassan Ali Emara (professor of hepatology, gastroenterology, and infectious diseases), Emad Fawzi Hamed (professor of internal medicine).

**E- Editor:** Salem Y Mohamed.

**Copyright** ©. This open-access article is distributed under the [**Creative Commons Attribution License (CC BY)**](http://creativecommons.org/licenses/by/4.0/). The use, distribution, or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited. The original publication in this journal is cited by accepted academic practice. No use, distribution, or reproduction is permitted, which does not comply with these terms.

**Disclaimer:**All claims expressed in this article are solely those of the authors and do not necessarily represent their affiliated organizations or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article or claim that its manufacturer may make is not guaranteed or endorsed by the publisher.

**References:**

**1-Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.** Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136: E359–86. https://doi.org/ 10.1002/ijc.29210.

**2-Soresi M., Terranova A., Licata A., et al. (2017**). " Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. " BioMed Research International Volume 2017, Article ID 4932759.

**3-Nowicki T, Markiet K and Szurowska E (2017).** "Diagnostic Imaging of Hepatocellular Carcinoma. " Current Medical Imaging Reviews, 2017, 13, 140-153.

**4-Qu, Q., Wang, S., Chen, S., Zhou, L. and Rui, J.-A. (2014).** "Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. " The American Surgeon, 80(2), 191-196.

**5-Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., et al. (2018).** "Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. " Hepatology, 68(2), 723-750.